HOWL
Werewolf Therapeutics, Inc.NASDAQHealthcare$1.01+2.97%ClosedMarket Cap: $49.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.93
P/S
0.00
EV/EBITDA
-0.53
DCF Value
$1.02
FCF Yield
-119.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-158.8%
ROA
-87.6%
ROIC
-96.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-9.4M | $-8.4M | $-0.17 | — |
| FY 2025 | $0.00 | -Infinity% | $-60.7M | $-60.8M | $-1.33 | — |
| Q3 2025 | $0.00 | NaN% | $-15.7M | $-16.4M | $-0.36 | — |
| Q2 2025 | $0.00 | -Infinity% | $-17.5M | $-18.0M | $-0.40 | — |
| Q1 2025 | $0.00 | -Infinity% | $-18.0M | $-18.1M | $-0.40 | — |
| Q4 2024 | $0.00 | NaN% | $-20.3M | $-20.4M | $-0.46 | — |
| FY 2024 | $1.9M | 3.8% | $-73.6M | $-70.5M | $-1.63 | — |
| Q3 2024 | $0.00 | NaN% | $-17.1M | $-16.7M | $-0.38 | — |
| Q2 2024 | $1.1M | 60.3% | $-19.0M | $-17.2M | $-0.40 | — |
| Q1 2024 | $742.0K | 37.5% | $-17.2M | $-16.2M | $-0.39 | — |
| Q4 2023 | $1.5M | 69.4% | $-13.0M | $-12.0M | $-0.33 | — |
| FY 2023 | $19.9M | 91.2% | $-40.5M | $-37.4M | $-1.05 | — |